Surrozen, Inc./DE Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
Surrozen, Inc./DE (SRZN) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 4.38 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2026-08-06
- Surrozen, Inc./DE incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2026-06-30 was 4.38M shares.
- Surrozen, Inc./DE incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2025-06-30 was 0.00 shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month |
|---|---|---|
| 2026-06-30 | 4.38M shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
| 2025-06-30 | 0.00 shares 10-Q · filed 2026-08-06 | 0.00 shares 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |